Simultaneous subcutaneous and conjunctival administration of the influenza viral vector based Brucella abortus vaccine to pregnant heifers provides better protection against B. abortus 544 infection than the commercial B. abortus S19 vaccine.
In this study, we explored possibility of increasing the protective efficacy of our novel influenza viral vector based B. abortus vaccine (Flu-BA) in pregnant heifers by adapting an innovative method of vaccine delivery. We administered the vaccine concurrently via the conjunctival and subcutaneous routes to pregnant heifers, and these routes were previously tested individually. The Flu-BA vaccination of pregnant heifers (n=9) against a challenge B. abortus 544 infection provided protection from abortion, infection of heifers and fetuses/calves by 88.8%, 100% and 100%, respectively (alpha=0.004-0.0007 vs. negative control; n=7). Our candidate vaccine using this delivery method provided slightly better protection than the commercial B. abortus S19 vaccine in pregnant heifers (n=8), which provided protection from abortion, infection of heifers and fetuses/calves by 87.5%, 75% and 87.5%, respectively. This improved method of the Flu-BA vaccine administration is highly recommended for the recovery of farms which has high prevalence of brucellosis.
The Research Institute for Biological Safety Problems, Zhambulskaya oblast, Kordaiskiy rayon, 080409 Gvardeisky, Kazakhstan. Electronic address: tabynov_81@mail.ru.
Kaissar
K
Tabynov
The Research Institute for Biological Safety Problems, Zhambulskaya oblast, Kordaiskiy rayon, 080409 Gvardeisky, Kazakhstan.
Mukhit
M
Orynbayev
Food Animal Health Research Program, Ohio Agricultural Research and Development Center, Department of Veterinary Preventive Medicine, The Ohio State University (OSU), Wooster, OH 44691, USA.
Gourapura J
GJ
Renukaradhya
The Research Institute for Biological Safety Problems, Zhambulskaya oblast, Kordaiskiy rayon, 080409 Gvardeisky, Kazakhstan.
Abylai
A
Sansyzbay
D037881:Aborted Fetus / Q000382:microbiology; D000034:Abortion, Veterinary / Q000382:microbiology / Q000517:prevention & control*; D000276:Adjuvants, Immunologic; D000279:Administration, Cutaneous; D060433:Administration, Ophthalmic; D000818:Animals; D002004:Brucella Vaccine / Q000008:administration & dosage* / Q000235:genetics; D002003:Brucella abortus / Q000276:immunology / Q000302:isolation & purification; D002007:Brucellosis, Bovine / Q000517:prevention & control*; D002417:Cattle; D003228:Conjunctiva; D005260:Female; D005315:Fetal Diseases / Q000517:prevention & control / Q000662:veterinary; D008198:Lymph Nodes / Q000382:microbiology; D009975:Orthomyxoviridae / Q000235:genetics*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000517:prevention & control / Q000662:veterinary*; D013154:Spleen / Q000382:microbiology; D014611:Vaccination / Q000662:veterinary; D014614:Vaccines, Synthetic / Q000008:administration & dosage
D000276:Adjuvants, Immunologic; D002004:Brucella Vaccine; D014614:Vaccines, Synthetic
Abortion; Brucella abortus; Infection; Influenza viral vector; Pregnant heifer; Protection; Vaccination method; Vaccine